ELI LILLY AND COMPANY Gain (Loss) on Disposition of Intangible Assets
ELI LILLY AND COMPANY (LLY) reported Gain (Loss) on Disposition of Intangible Assets of $180.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfIntangibleAssets · last filed 2026-02-12
- ELI LILLY AND COMPANY gain (loss) on disposition of intangible assets for the quarter ending 2024-12-31 was $123.30M, a 391.24% increase year-over-year.
- ELI LILLY AND COMPANY gain (loss) on disposition of intangible assets for the quarter ending 2023-12-31 was $25.10M, a 59.52% decline year-over-year.
- ELI LILLY AND COMPANY gain (loss) on disposition of intangible assets for the quarter ending 2022-12-31 was $62.00M.
- ELI LILLY AND COMPANY gain (loss) on disposition of intangible assets for fiscal 2025 was $180.00M, a 19.64% decline from fiscal 2024.
- ELI LILLY AND COMPANY gain (loss) on disposition of intangible assets for fiscal 2024 was $224.00M, a 88.08% decline from fiscal 2023.
- ELI LILLY AND COMPANY gain (loss) on disposition of intangible assets for fiscal 2023 was $1.88B, a 1100.64% increase from fiscal 2022.
- ELI LILLY AND COMPANY gain (loss) on disposition of intangible assets for fiscal 2022 was $156.50M, a 27.55% decline from fiscal 2021.
| Period end | Gain (Loss) on Disposition of Intangible Assets 3 month | Gain (Loss) on Disposition of Intangible Assets 9 month | Gain (Loss) on Disposition of Intangible Assets 12 month | Gain (Loss) on Disposition of Intangible Assets 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | $180.00M 10-K · filed 2026-02-12 | |||
| 2024-12-31 | $123.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $224.00M 10-K · filed 2026-02-12 | $223.80M 10-K · filed 2025-02-19 | |
| 2024-09-30 | $100.70M 10-Q · filed 2024-10-30 | |||
| 2023-12-31 | $25.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.88B 10-K · filed 2026-02-12 | $1.88B 10-K · filed 2024-02-21 | |
| 2023-09-30 | $1.85B 10-Q · filed 2024-10-30 | |||
| 2022-12-31 | $62.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $156.50M 10-K · filed 2025-02-19 | ||
| 2022-09-30 | $94.50M 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | $216.00M 10-K · filed 2024-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |